Search results for Theragen

Theragen Receives First European Patent for ActaStimВ®-S

Top 10 Best Selling Gene Therapies

As more products reach the market, therapy developers partner with researchers and regulators to deliver N-of-1 treatments to patients. The post Top 10 Best Selling Gene Therapies...

Theragen Receives First European Patent for ActaStim®-S

Company’s BGS Is Most Advanced Device in Categoryin More than Two Decades Jacksonville, FL, April 28, 2026 /OrthoSpineNews/…

Geron

Geron Anonymous (not verified) Sun, 04/19/2026 - 08:10 field_thread_url https://cafepharma.com/boards/threads/geron.694511/ board name...

<![CDATA[Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals ]]>

Regeneron, Telix Launch Up-to-$4.3B Cancer-Focused Radiopharma Drug, Diagnostic Collaboration

The companies have agreed to partner on next-generation radiopharmaceutical therapies aimed at up-to-eight solid tumor targets from Regeneron’s portfolio of antibodies, generated f...

Andelyn Partners with S. Korea-Based ENCell to Accelerate Global Delivery of Gene Therapies

The partnership leverages both companies’ GMP manufacturing facilities, technical expertise, and regional networks to fast-track the development, manufacturing, and global expansio...

Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer

The partnership will automate manufacturing and quality control of ProT-096, ProTgen’s personalized progenitor T-cell therapy for refractory leukemia and other hematologic malignan...

Transforming neurodegenerative disease treatment

Discover how Cognition Therapeutics is redefining hope for Alzheimer’s and Dementia with Lewy bodies [JG1] with innovative, accessible therapies.

Seer Joins Thermo Fisher Tools In Large-Scale Proteomics Effort

Seer Proteograph platform joins Singapore study to profile 10,000 samples, integrating data for disease research and risk modeling. Importance Rank: ...

Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix

With its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals.

Argenx

Argenx Anonymous (not verified) Sat, 05/30/2026 - 14:41 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

<![CDATA[Neurocrine Enters $2.9 Billion Agreement to Acquire Soleno Therapeutics ]]>

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

WA biotech duo takes aim at diabetes beyond Ozempic

A WA biotech duo, ProGenis and Syngenis Laboratories, is developing RNA-based therapies at the next frontier in diabetes medicine, while building Australia’s first RNA facility.